Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Insulin Formulations: Types and Delivery

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...

Insulin: Biosynthesis, Chemistry, and Preparation

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

One-Compartment Open Model for IV Bolus Administration: General Considerations

One-Compartment Open Model for IV Bolus Administration: General Considerations

The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...

Insulin Secretory Vesicles

Insulin Secretory Vesicles

Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Safety and glycemic outcomes of DBLG1 coupled to the DANA-i pump in adults and adolescents with type 1 diabetes mellitus. The SP8 trial.

Journal of endocrinological investigation·2025

Same author

Practical implementation of automated insulin delivery systems in 2025: A French position statement update.

Diabetes & metabolism·2025

Same author

Discovery of a TRMT10A mutation in a case of atypical diabetes: Case report.

Diabetes & metabolism·2024

Same author

Cutaneous hypersensitivity reaction to dulaglutide: A case report of an allergic reaction.

Diabetes & metabolism·2024

Same author

Spatial multi-criteria decision analysis for the selection of sentinel regions in tick-borne disease surveillance.

BMC public health·2024

Same author

Real world evidence of the efficacy of two hybrid closed loop systems for children and adults with type 1 diabetes with some clinical warnings.

Diabetes & metabolism·2022

Search research articles

Related Experiment Video

Updated: Dec 2, 2025

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Practical implementation of automated closed-loop insulin delivery: A French position statement.

N Tubiana-Rufi¹, P Schaepelynck², S Franc³

¹Endocrinologie et Diabétologie Pédiatrique, Hôpital Robert Debré, APHP Nord, Université de Paris et Aide aux Jeunes Diabétiques AJD, Paris, et SFEDP, France.

Diabetes & Metabolism

|November 5, 2020

Summary

Automated closed-loop (CL) insulin therapy is now a reality for type 1 diabetes. This consensus statement from the French Diabetes Society outlines its indications, expert care requirements, and training needs for improved patient outcomes.

Keywords:

Adolescents Adults Artificial pancreas Automated closed-loop insulin delivery Children Closed-loop Organization of care Position statement SFD Therapeutic education Type 1 diabetes

More Related Videos

An In Ovo Model for Testing Insulin-mimetic Compounds

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Three-dimensional Printing of Thermoplastic Materials to Create Automated Syringe Pumps with Feedback Control for Microfluidic Applications

Three-dimensional Printing of Thermoplastic Materials to Create Automated Syringe Pumps with Feedback Control for Microfluidic Applications

Published on: August 30, 2018

Related Experiment Videos

Last Updated: Dec 2, 2025

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

An In Ovo Model for Testing Insulin-mimetic Compounds

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Three-dimensional Printing of Thermoplastic Materials to Create Automated Syringe Pumps with Feedback Control for Microfluidic Applications

Three-dimensional Printing of Thermoplastic Materials to Create Automated Syringe Pumps with Feedback Control for Microfluidic Applications

Published on: August 30, 2018

Area of Science:

Endocrinology
Diabetes Technology
Medical Device Regulation

Background:

Automated closed-loop (CL) insulin therapy represents a significant advancement in type 1 diabetes management.
Improving access and adherence to CL therapy requires clear guidelines for patients and healthcare professionals.
The French Diabetes Society (SFD) convened an expert working group to establish a practical consensus.

Purpose of the Study:

To define the indications for automated closed-loop insulin therapy.
To propose specifications for expert care centers initiating CL therapy.
To emphasize the importance of patient and healthcare professional training and long-term follow-up.

Main Methods:

Development of a national consensus statement by a French Working Group of experts.
Discussion and agreement on practical aspects of CL therapy implementation.
Inclusion of safety, regulatory, ethical, and practical considerations.

Main Results:

Defined indications for CL therapy, stressing the need for clear treatment expectations.
Proposed specifications for expert care centers responsible for initiating CL therapy.
Highlighted the critical role of high-quality training for patients and HCPs.

Conclusions:

Automated closed-loop insulin therapy is poised to enhance care for individuals with type 1 diabetes.
This consensus statement provides a framework for integrating CL devices into standard clinical practice.
Emphasis on defined expectations, specialized care, comprehensive training, and psychosocial factors is crucial for successful adoption.